Has Steven Bobula, MD received payments from drug or device companies?

Yes. Drug and device makers reported $33,825 in general payments to Steven Bobula, MD across 351 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Steven Bobula, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Steven Bobula, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Steven Bobula, MD

Infectious Disease · Westerville, OHNPI 1700097565

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $21,240 of the $33,825 with a category attached, or 62.8%. AbbVie accounts for 60.8% of it on its own, with 24 other manufacturers making up the rest. Reporting peaked in 2021 at $9,002 and has fallen 89.1% since, to $984 in 2025. Among infectious disease clinicians in OH with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$33,825in general payments, 2019–2025

Across 351 payments — averaging $96.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

AbbVie$21K
Merck$5K
Insmed, Inc.$4K
CSL Behring$1K
Organogenesis Inc.$1K
Viiv Healthcare Company$716
plus $2K from 19 others

What the payments were for

Consulting fees$3,25110%
Speaking & faculty fees$21,24063%
Travel & lodging$1,5024%
Food & beverage$7,69323%
Education$1390%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
AbbVie(2 entities)	117	$20,578
Merck	46	$4,739
Insmed, Inc.	18	$3,643
CSL Behring	51	$1,375
Organogenesis Inc.	19	$1,264
Viiv Healthcare Company	33	$716
Smith+Nephew	15	$385
Melinta Therapeutics, LLC	13	$204
Solventum Corporation	1	$129
Shionogi Inc	5	$105
Astellas Pharma US Inc	3	$102
Gilead	5	$90
Aimmune Therapeutics, Inc.	3	$83
Paratek Pharmaceuticals, Inc.	4	$73
Kerecis Limited	2	$62
Tetraphase Pharmaceuticals, Inc.	3	$53
KCI USA, Inc.	2	$52
La Jolla Pharmaceutical Company	2	$39
Cumberland Pharmaceuticals, Inc.	2	$29
Theratechnologies Inc.	2	$28
Normatec Industries, LP	1	$21
Aroa Biosurgery Incorporated	1	$17
Pfizer	1	$14
Dynavax Technologies Corporation	1	$13
Mayne Pharma Commercial LLC	1	$11

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$33,825 in reported general payments places this provider in the 95th percentile of 308 infectious disease providers in Ohio.

See all infectious disease providers in Ohio →

Medicare billing

Part B allowed, 2024

$118,053

Medicare patients

355

Services billed

1,625

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Daptomycin	79	$35,783
Meropenem	66	$24,902
ErtapenemErtapenem Sodium	42	$19,030
Vancomycin Hcl	61	$15,442
Piperacillin-TazobactamPiperacillin Sodium/Tazobactam	38	$10,277
Cefepime Hcl	23	$5,486
MicafunginMicafungin Sodium	17	$3,664
Ampicillin-SulbactamAmpicillin Sod/Sulbactam Sod	39	$2,765
Doxycycline Hyclate	124	$2,459
CeftriaxoneCeftriaxone Sodium	21	$2,264
Lactated RingersRinger's Solution,lactated	43	$2,253
Linezolid	13	$1,889
Cefdinir	48	$1,429
Ceftazidime	14	$1,428
Cefazolin Sodium	24	$1,051

Paid to pharmacies, not to this prescriber.

Other infectious disease in Westerville

Jane EmerickWesterville$5K
Steven BurdetteDayton$322K
Nathaniel RatnasamyFindlay$255K
Melissa JenkinsCleveland$127K
Grace McComseyCleveland$123K
Steven GordonCleveland$78K
Nicholas CongerWright Patterson Afb$76K
Alan TaegeCleveland$76K
Carlos MalvestuttoColumbus$70K
Thomas FileAkron$68K

See the full list for Ohio →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →